Navigation Links
Cord blood cells may widen treatment window for stroke

An experimental treatment that spares disability from acute stroke may be delivered much later than the current three-hour treatment standard ?a potential advance needed to benefit more stroke victims.

Researchers at the University of South Florida found that human umbilical cord blood cells administered to rats two days following a stroke greatly curbed the brain's inflammatory response, reducing the size of the stroke and resulting in greatly improved recovery. The rats' inflammatory response to injury from stroke peaked 48 hours after the brain attack, which was when intravenous delivery of the cells appeared most beneficial.

"We were very surprised," said principal investigator Alison Willing, PhD, a neuroscientist at the USF Center of Excellence for Aging and Brain Repair. "In some animals, the stroke initially damaged half the brain, but after treatment with the cord blood cells they were functioning normally.

"These findings show we are able to rescue neurons at a time when most research suggests they are already dead."

Dr. Willing presented the preliminary findings Nov. 12 at the Society for Neuroscience annual meeting in Washington, DC.

The only drug currently approved for ischemic stroke treatment is tPA (tissue plasminogen activator), which breaks up blood clots ?the cause of most strokes. However, tPA must be given within three hours following a stroke to be effective and few patients arrive at the hospital quickly enough to receive it. Even when a patient meets the recommended three-hour treatment criteria, smaller hospitals often lack ready access to a CT scan, a test needed to rule out a hemorrhagic stroke caused by a burst blood vessel. The drug can worsen this less common type of stroke.

"New and more flexible treatments are needed to help more patients," Dr. Willing said. "Cord blood treatment in rats is successful in alleviating, even eliminating, the disabling effects of both ischemic and hemorrhagic stroke. What's more, the treatment can be delivered much later than the current strict three-hour therapeutic window."

The USF study challenges the notion that nerve cells inevitably die quickly in the core region of the brain most severely deprived of oxygen and nutrients when a stroke hits. Instead, the researchers suggest, many nerve cells within ground zero of the attack, like those in mild to moderately damaged outlying areas, may succumb over several days through a slower, more orderly process known as apoptosis, or programmed cell death.

"This delayed death would permit more time to deliver neuron-sparing treatments than originally thought," Dr. Willing said.

The USF researchers continue to investigate the ways cord blood cells aid stroke recovery in animals, and will begin a study to determine the timing of brain inflammatory responses in acute stroke patients.

Researchers working with Dr. Willing were Jennifer Newcomb, Ted Ajmo, Lisa Collier, Cyndy Davis Sanberg, PhD; Keith Pennypacker, PhD; and Paul R. Sanberg, PhD, DSc. The USF study was conducted with Saneron CCEL Therapeutics, a USF-spinout biotechnology company developing cell therapies for deadly and debilitating disorders. Dr. Sanberg is a cofounder of Saneron CCEL, and Dr. Willing is a consultant.


'"/>

Source:University of South Florida Health


Related biology news :

1. White blood cell waste disposal system plays critical regulatory role
2. Epstein-Barr virus protein crucial to its role in blood cancers
3. New insight into regulation of blood stem cells
4. Nano-bumps could help repair clogged blood vessels
5. First technology to remove prions that cause vCJD from blood launched
6. Breakthrough isolating embryo-quality stem cells from blood
7. Thai spice helps cut blood sugar swings
8. Study shows humans have ability to track odors, much like bloodhounds
9. Mad cow proteins successfully detected in blood
10. Unexpected lock and key mechanism found for the assembly of tumor blood vessels
11. Redesigned protein accelerates blood clotting
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... PA (PRWEB) , ... February 09, 2016 , ... Tunnell ... Europe. Based in Paris, he will focus on acquiring new accounts and work ... met. , “Fred brings to our European clients more than 15 ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/8/2016)... , Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: ... the top ten finalists for clean technology companies in the ... the top 10 companies listed on the TSX Venture Exchange, ... & gas, clean technology & life sciences, diversified ... equal weighting given to return on investment, market cap growth, ...
Breaking Biology Technology: